SOLIQUA (insulin glargine/lixisenatide) Patient Assistance Program
Don’t let the high cost of brand fixed-ratio basal insulin/GLP-1 RA combination therapy disrupt your diabetes management. We help eligible patients access Soliqua (insulin glargine/lixisenatide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Soliqua 100/33 (insulin glargine 100 units/mL + lixisenatide 33 mcg/mL) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on basal insulin (<60 units daily) or lixisenatide. It is a once-daily fixed-ratio combination of basal insulin glargine and the GLP-1 receptor agonist lixisenatide.
- Without assistance, brand Soliqua costs commonly run approximately $700–$900 per 5-pen pack (one month).
- Through AffordMyPrescriptions, qualifying patients can access Soliqua for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Soliqua in the U.S. as of 2026. The other fixed-ratio basal insulin/GLP-1 RA combination is Xultophy (insulin degludec + liraglutide). Components can also be used separately: generic insulin glargine biosimilars (Semglee, Rezvoglar) are widely available at much lower cost; GLP-1 RAs (oral semaglutide/Rybelsus, injectable semaglutide/Ozempic, dulaglutide/Trulicity, tirzepatide/Mounjaro) are typically more potent than lixisenatide. Medicare Part D $35/month insulin cap applies to Soliqua.
What Is Soliqua Prescription Assistance Program?
The Soliqua Prescription Assistance Program is a manufacturer-sponsored initiative that provides Soliqua at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for type 2 diabetes patients requiring intensified therapy who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, endocrinology/primary care coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Soliqua costs roughly $700–$900 per 5-pen pack. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$870 | Save ~$800/mo |
| CVS Pharmacy | ~$900 | Save ~$830/mo |
| Walmart | ~$740 | Save ~$670/mo |
| Costco | ~$720 | Save ~$650/mo |
Medicare Part D cap | $35/mo | Federal cap |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Soliqua Prescription Program?
The Patient Assistance Program is free to apply for and provides Soliqua at no medication cost if approved. Our $69.95/month service covers full advocacy. With biosimilar insulin glargine (Semglee, Rezvoglar) available at much lower cost and Medicare’s $35/month insulin cap, we’ll help your provider determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Soliqua:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $700–$900 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Soliqua assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Soliqua Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Soliqua:
Soliqua 100/33 is a once-daily fixed-ratio combination of insulin glargine (long-acting basal insulin) and lixisenatide (short-acting GLP-1 receptor agonist) in a single prefilled pen for subcutaneous injection. The combination provides both basal insulin coverage and GLP-1 RA effects in one daily injection.
How Soliqua Works:
Type 2 diabetes inadequately controlled on basal insulin alone often benefits from adding a GLP-1 receptor agonist — which improves glucose control with less weight gain and less hypoglycemia than escalating basal insulin. Combining basal insulin + GLP-1 RA in one injection simplifies the regimen.
Insulin glargine is a long-acting basal insulin analog that provides 24-hour basal insulin coverage. Lixisenatide is a short-acting GLP-1 receptor agonist that increases glucose-dependent insulin secretion, slows gastric emptying, reduces glucagon secretion, and promotes satiety — particularly addressing post-meal glucose. Together, basal insulin glargine controls fasting glucose; lixisenatide controls post-meal glucose. The fixed-ratio combination titrates both components proportionally — dosing is based on the insulin component (units), with lixisenatide following at the fixed ratio.
Form and use:
Soliqua is injected subcutaneously once daily, within one hour before the first meal of the day. Dose titration is based on fasting glucose, similar to titrating insulin glargine alone. Available in SoloStar prefilled pens (one pen = 3 mL = 300 units insulin glargine + 100 mcg lixisenatide). Dose range: 15–60 units daily. Rotate injection sites.
Generic availability:
There is no biosimilar of Soliqua in the U.S. as of 2026. The other fixed-ratio basal insulin/GLP-1 RA combination is Xultophy 100/3.6 (insulin degludec + liraglutide). Components can be used separately: insulin glargine has biosimilars (Semglee — interchangeable; Rezvoglar) at much lower cost than brand Lantus or Soliqua. GLP-1 RAs include short-acting (Adlyxin/lixisenatide, oral semaglutide/Rybelsus) and longer-acting/more potent options (Ozempic/semaglutide, Trulicity/dulaglutide, Mounjaro/tirzepatide) with stronger glycemic and weight benefits.
Warnings:
Soliqua carries warnings for both components. Insulin-related: hypoglycemia (most common; monitor BG), hypokalemia, fluid retention/heart failure with TZD combinations. GLP-1 RA-related: pancreatitis (rare but serious — discontinue if pancreatitis suspected), thyroid C-cell tumors (boxed warning class effect — Soliqua contraindicated in personal or family history of medullary thyroid cancer or MEN2), hypersensitivity, severe GI side effects (nausea, vomiting, diarrhea), acute gallbladder disease, acute kidney injury (related to dehydration from GI side effects), diabetic retinopathy worsening, and rare suicidal ideation reports.
FAQ (Frequently Asked Questions)
How Much Does Soliqua Cost Without Insurance?
Brand Soliqua costs approximately $700–$900 per 5-pen pack (one month). Medicare Part D beneficiaries pay $35/month maximum for covered insulin (which includes Soliqua). Through AffordMyPrescriptions, qualifying patients receive Soliqua at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Combine Basal Insulin And A GLP-1 RA?
Type 2 diabetes inadequately controlled on basal insulin often benefits from adding a GLP-1 RA — which lowers A1c further with less weight gain and less hypoglycemia than escalating insulin alone. Combining them in one daily injection (Soliqua or Xultophy) simplifies the regimen — but limits flexibility (can’t independently titrate insulin and GLP-1 RA). Some patients prefer separate insulin and a more potent GLP-1 RA (Ozempic, Mounjaro).
How Is Soliqua Different From Xultophy?
Both are fixed-ratio basal insulin/GLP-1 RA combinations. Soliqua = insulin glargine + lixisenatide (short-acting GLP-1 RA, dosed once daily before first meal). Xultophy = insulin degludec + liraglutide (longer-acting GLP-1 RA, dosing time flexible). Choice depends on patient preference, insurance coverage, and provider familiarity. Liraglutide may have slightly stronger glycemic effects than lixisenatide.
Should I Consider Ozempic Or Mounjaro Instead?
Possibly. Ozempic (semaglutide) and Mounjaro (tirzepatide — a dual GIP/GLP-1 agonist) are more potent GLP-1 RA-class agents than lixisenatide — typically producing greater A1c reduction and more weight loss. For type 2 diabetes patients with significant cardiovascular disease, kidney disease, or substantial weight to lose, the more potent GLP-1 RAs are often preferred — alongside separate basal insulin if needed. Discuss with your provider whether your regimen is optimal.
What About The Medicare $35 Insulin Cap?
Effective January 1, 2023, Medicare Part D capped patient out-of-pocket cost at $35/month per covered insulin product, including insulin combination products like Soliqua. Most Medicare beneficiaries pay $35/month for Soliqua under Part D.
Will I Have Side Effects?
The main GLP-1 RA side effects (nausea, vomiting, decreased appetite, occasional diarrhea) are present with Soliqua — typically prominent at start of therapy or with dose increases, then improving over time. Insulin-related hypoglycemia is possible (monitor BG; carry rapid glucose). Severe pancreatitis is rare but possible — tell your provider about severe abdominal pain. Avoid Soliqua if personal or family history of medullary thyroid cancer.
What If My Application Is Denied?
If denied, we explore alternatives — switching to biosimilar insulin glargine (Semglee, Rezvoglar) plus a generic or branded GLP-1 RA separately, switching to Xultophy or to standalone Ozempic/Trulicity/Mounjaro plus basal insulin, the manufacturer’s copay program for commercially insured patients, Medicare $35/month cap if applicable, or independent foundations such as the American Diabetes Association, JDRF, or PAN Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Soliqua, our team may be able to help you access assistance programs — or guide you to a more affordable basal insulin + GLP-1 RA approach. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.